Résumé
Objective To investigate the neurological and cerebrospinal fluid interleukin-6 effects of butylphthalide on brain hemorrhage.Methods Ninety cerebral hemorrhage patients in principle based on a random draw were equally divided into the treatment group (45 cases) and the control group (45 cases).Two groups were given basic treatment, the control group were treated with nimodipine tablets adjuvant therapy, the treatment group were treated with butylphthalide soft capsules adjuvant therapy, all patients were treated for 30 days.Results After treatment, the national institutes of health stroke scale (NIHSS) score was shown significant downward trend in the two groups((9.45±0.44) to (2.09±0.45) scores;(9.44±0.21) to (4.58±0.65) scores) and compared with pre-treatment differences were significant (t=16.983, P=0.000;t =8.112, P =0.000), and the NIHHS score in treatment group was significantly lower than in control group(P =0.000).The mini-mental state examination (MMSE) score and activities of daily living (ADL) scores were shown significant upward trend in the two groups,compared with pre-treatment differences were significant(P ＜0.05).MMSE score(26.98±3.91) and ADL scores(34.29±6.42) scores in the treatment group were significantly lower in the control group((23.09±5.33) scores, (30.28±5.33)scores) after treatment(t =6.498, P =0.000;t =8.123, P =0.000).After treatment, the values cerebrospinal fluid interleukin-6 (IL-6) expression in the two groups were significantly reduced (P ＜ 0.05), while the value of cerebrospinal fluid IL-6 expression in the treatment group were significantly lower than the control group ((45.38 ± 13.02) ng/L vs (122.87± 17.42) ng/L, t =18.334, P =0.000).The adverse reactions of the two groups were mild, and were significantly improved after symptomatic treatment.Conclusion Butylphthalide adjuvant treatment of cerebral hemorrhage can improve nerve function, cognitive function and activities of daily living, its safety is also better.It plays its role may related to effectively reduce the IL-6 expression.